脓毒症心肌损伤生物标志物研究进展
脓毒症是感染引起宿主反应失调导致的急性器官功能障碍综合征,常并发多器官损伤。约40%的脓毒症患者发生心肌损伤,未及时识别和处理可能导致错过治疗窗口、病情恶化和死亡率增加。脓毒症诱导的心肌损伤是可逆的,早期诊断联合及时干预可显著降低死亡率。但由于病理生理机制不明确且缺乏诊断金标准,传统心肌损伤标志物诊断价值有限。本文综述了脓毒症心肌病相关传统和新型生物标志物的最新研究进展,为临床应用和未来研究方向提供见解。
要点
- 约40%的脓毒症患者发生心肌损伤,未及时识别和处理可能导致错过治疗窗口、病情恶化和死亡率增加。
- 脓毒症诱导的心肌损伤是可逆的,早期诊断联合及时干预可显著降低死亡率。
- 由于病理生理机制不明确且缺乏诊断金标准,传统心肌损伤标志物诊断价值有限。
- 高迁移率族蛋白B1、微小RNA和生长分化因子15等新兴标志物正在探索用于早期检测和预后评估。
适用人群与场景
- 脓毒症患者,约40%发生心肌损伤。
红旗征与不能漏的情况
- 脓毒症患者发生心肌损伤若未及时识别和处理,可能导致错过治疗窗口、病情恶化和死亡率增加。
研究设计与关键结果
- 综述总结了脓毒症心肌病相关传统和新型生物标志物的最新研究进展。
- 传统心肌损伤标志物因病理生理机制不明确且缺乏诊断金标准而诊断价值有限。
- 高迁移率族蛋白B1、微小RNA和生长分化因子15等新兴标志物正在探索用于早期检测和预后评估。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 脓毒症患者中约40%发生心肌损伤,早期诊断联合及时干预可显著降低死亡率,但传统心肌损伤标志物诊断价值有限。
- 高迁移率族蛋白B1、微小RNA和生长分化因子15等新兴标志物正在探索用于早期检测和预后评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis is a life-threatening syndrome characterized by acute organ dysfunction caused by a dysregulated host response to infection, often complicated by multi-organ injury. Myocardial injury occurs in approximately 40% of patients with sepsis, and failure to promptly recognize and manage this condition may result in missed treatment windows, disease exacerbation, and increased mortality. Sepsis-induced myocardial injury is reversible, and early diagnosis coupled with timely intervention can significantly reduce mortality. However, due to the unclear underlying pathophysiology and the absence of a definitive gold standard for diagnosis, conventional biomarkers of myocardial injury offer limited diagnostic utility. Emerging biomarkers such as high-mobility group box 1 protein, microRNAs, and growth differentiation factor 15 are currently being explored to understand their potential role in early detection and prognostic assessment. In this review, recent research advances in both traditional and novel biomarkers associated with sepsis-induced cardiomyopathy have been summarized, providing insights into their clinical applications and future research directions.
参考来源
- Yang L, Feng JK, Gong PX, et al. Advances in Research Pertaining to Biomarkers for Myocardial Injury in Sepsis. Shock. 2025. PMID: 40705395. doi:10.1097/SHK.0000000000002678
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。